<DOC>
	<DOCNO>NCT00984542</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , bendamustine , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well bendamustine work second- third-line therapy treat patient relapse refractory small cell lung cancer .</brief_summary>
	<brief_title>Bendamustine Second-Line Therapy Treating Patients With Relapsed Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine time progression patient relapse refractory small cell lung cancer treat second- third-line bendamustine . Secondary - To determine toxicity drug patient . - To determine response rate , progression-free survival , overall survival patient treated drug . OUTLINE : This multicenter study . Patients receive bendamustine IV 1 hour day 1 2 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6-8 week .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer Relapsed refractory disease 12 prior chemotherapy regimens Measurable disease ECOG Eastern Cooperative Oncology Group performance status 02 ANC ≥ 1,500/mm³ : ANC = Absolute neutrophil count Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Bilirubin normal AST/ALT ≤ 2 time upper limit normal ( ULN ) ( ≤ 5 time ULN patient hepatic metastasis ; AST/ALT = alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) Creatinine clearance &gt; 40 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception , , ≥ 3 month completion study therapy No known hypersensitivity bendamustine No malignancy patient treat within past year except nonmelanoma skin cancer carcinoma situ cervix No cardiac disease , include follow : Unstable angina pectoris Lifethreatening cardiac arrhythmia Symptomatic congestive heart failure No uncontrolled infection No concurrent chemotherapy , immunotherapy , antitumor hormonal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>